2018 Advisory Committee

Tiffany Brosius, RN, BSN, OCN, is a nurse navigator working with patients with gastrointestinal malignancies at Winship Cancer Institute.

An oncology-certified nurse, Mrs. Brosius began her nursing career as an outpatient chemotherapy infusion nurse at University Cancer and Blood Center in Athens, Georgia. She relocated to Atlanta, Georgia, and accepted a position as a Nurse Clinician on the medical oncology floor at Emory University Hospital. She then transitioned back to the outpatient setting to continue her nursing career as an Advanced Nurse Clinician at Winship Cancer Institute, focusing on gastrointestinal malignancies. In this role, she assisted patients with symptom management and chemotherapy education.

She is a local and national member of the Oncology Nursing Society and was recently accepted as a member to Sigma Theta Tau International Honor Society, Alpha Epsilon Chapter at Emory University.

She received a Bachelor of Science in Nursing from Georgia Regents University, formerly known as the The Medical College of Georgia.

Melanie Thomas, MD, is a medical oncologist, clinical researcher, and Associate Director for Experimental Therapeutics at Gibbs Cancer Center & Research Institute, Spartanburg Regional Healthcare System, Spartanburg, South Carolina. Her research has included clinical trials in solid tumors through the National Cancer Institute (NCI), pharmaceutical industry, NCTN cooperative groups, investigator initiated, and Phase I trials of novel agents, all of which have been published in peer-reviewed oncology journals. Dr. Thomas has led numerous clinical trials in hepatocellular carcinoma and other gastrointestinal cancers and is an internationally recognized expert in these malignancies. She received the NCI Clinical Investigator Team Leadership Award 2009-2010.

Dr. Thomas attended Boston University School of Medicine, completed internal medicine residency at The Beth Israel Deaconess Medical Center in Boston, and spent nine years at The University of Texas M.D. Anderson Cancer Center as a medical oncology fellow and faculty member. Previously she was Associate Director, Clinical Investigations, Hollings Cancer Center, Medical University of South Carolina. From 2007-2014 she was President of CanLiv – The Hepatobiliary Cancers Foundation, now part of The Global Liver Institute.

Matthew Dugan, DO, is a medical oncologist at New England Cancer Specialists, where he specializes in all cancers of the digestive system, and head and neck. Dr. Dugan serves as an associate instructor for Tufts University School of Medicine, the University of Vermont, and the University of New England. Principal investigator on multiple industry and cooperative group clinical trials, Dr. Dugan has also published works in the New England Journal of Medicine and Cancer Investigation.

Anurag Maheshwari, MD, specializes in liver disease at the Center for Liver and Hepatobiliary Diseases, part of the Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center in Baltimore, Maryland. His expertise helps patients in the diagnosis and treatment of liver diseases.

Dr. Maheshwari helps patients in need of liver transplants and assists in pre- and post-operative transplant medical care, providing each patient individualized attention, coordination with liver transplant centers, and understanding as they progress toward recovery.

Dr. Maheshwari is active in advanced research projects in liver diseases, having authored numerous peer-reviewed publications and book chapters on issues in liver disease.

Dr. Philip is a Kathryn Cramer MD Endowed Professor in Cancer Research at the Wayne State University School of Medicine and the leader of the GI and neuroendocrine multidisciplinary team and Vice President of medical affairs at the Karmanos Cancer Institute. He is also a fellow of the Royal College of Physicians in the UK and Chair of the pancreatic cancer committee at the Southwest Oncology Group (SWOG). An internationally-recognized lecturer, Dr. Philip is known for his research in the development of new therapies for gastrointestinal and neuroendocrine cancers.